Innoviva (INVA) Net Equity Issued and Repurchased (2010 - 2026)
Innoviva (INVA) posted Net Equity Issued and Repurchased of $259000.0 for Q1 2026, down 84.9% on a QoQ basis from $1.7 million in Q3 2025, and up 3.6% year-over-year from $250000.0 in Q1 2025.
Innoviva (INVA) Net Equity Issued and Repurchased (2010 - 2026) Analysis & Trends
Innoviva's Net Equity Issued and Repurchased history runs 17 years deep, the most recent figure standing at $259000.0 for Q1 2026.
- Quarterly Net Equity Issued and Repurchased rose 3.6% year-over-year to $259000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.5 million (up 97.57% YoY) and the FY2025 annual result came in at $2.6 million, up 74.15% from the prior year.
- Net Equity Issued and Repurchased was $259000.0 for Q1 2026 at Innoviva, down from $1.7 million in the prior quarter.
- Across five years, Net Equity Issued and Repurchased topped out at $1.7 million in Q3 2025 and bottomed at $81000.0 in Q2 2022.
- A 5-year average of $493250.0 and a median of $259500.0 in 2022 frame the typical range for Net Equity Issued and Repurchased.
- Annual changes were most pronounced in 2023 — Net Equity Issued and Repurchased plunged 67.54% — and 2025, when it soared 709.55%.
- Innoviva's Net Equity Issued and Repurchased stood at $342000.0 in 2022, then plunged by 67.54% to $111000.0 in 2023, then soared by 687.39% to $874000.0 in 2024, then jumped by 96.22% to $1.7 million in 2025, then tumbled by 84.9% to $259000.0 in 2026.
- Business Quant data shows INVA's Net Equity Issued and Repurchased at $259000.0 in Q1 2026, $1.7 million in Q3 2025, and $1.3 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 163.10 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 141.90 Mn |
| 10 | Innoviva | 1.57 Bn | 969.11 Mn | 75.83 Mn | 259,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 259,000.00 |
| Mar 31, 2026 | 259,000.00 |
| Sep 30, 2025 | 1.72 Mn |
| Sep 30, 2025 | 1.72 Mn |
| Jun 30, 2025 | 1.27 Mn |
| Jun 30, 2025 | 1.27 Mn |
| Mar 31, 2025 | 250,000.00 |
| Mar 31, 2025 | 250,000.00 |
| Sep 30, 2024 | 874,000.00 |
| Sep 30, 2024 | 874,000.00 |
| Jun 30, 2024 | 157,000.00 |
| Jun 30, 2024 | 157,000.00 |
| Mar 31, 2024 | 488,000.00 |
| Mar 31, 2024 | 488,000.00 |
| Sep 30, 2023 | 111,000.00 |
| Sep 30, 2023 | 111,000.00 |
| Jun 30, 2023 | 111,000.00 |
| Jun 30, 2023 | 111,000.00 |
| Sep 30, 2022 | 342,000.00 |
| Sep 30, 2022 | 342,000.00 |